Psychopharmacologic Treatment of Schizophrenia

  • John M. Kane
Part of the International Perspectives Series: Psychiatry, Psychology, and Neuroscience book series


The introduction of pharmacologic treatments for schizophrenia remains one of the major advances of twentieth century medicine. Despite the availability and efficacy of these compounds the treatment of schizophrenia continues to pose numerous challenges to clinicians, not only because of its prevalence, severity, and complexity, but also because its treatment requires an integration of a variety of different prospectives (eg, biological, psychological, and psychosocial).1 Other chapters in this book have reviewed data relating to phenomenologic, genetic, neuroanatomic, psychophysiologic, and psychosocial aspects of this illness, providing extensive documentation of both its complexity and its probable heterogeneity.


Antipsychotic Drug Negative Symptom Tardive Dyskinesia Brief Psychiatric Rate Scale Extrapyramidal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kane JM: Treatment of schizophrenia. Schizophr Bull 1987;13:147–171.Google Scholar
  2. 2.
    Davis JM, Schaffer CB, Killian GA, et al: Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70–87.PubMedGoogle Scholar
  3. 3.
    Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins, 1969.Google Scholar
  4. 4.
    Gardos G: Are antipsychotic drugs interchangeable? J Nerv Ment Dis 1978;159:343–348.Google Scholar
  5. 5.
    Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481–483.PubMedCrossRefGoogle Scholar
  6. 6.
    Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1985;45:331–336.Google Scholar
  7. 7.
    Davis JM, Barder J, Kane JM: Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds): Comprehensive Textbook of Psychiatry, ed 5. Baltimore, Williams & Wilkins, 1989, pp. 1591–1626.Google Scholar
  8. 8.
    Van Putten T, Marder SR, Mintz J: The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharmacol Bull 1987,23:201–205.PubMedGoogle Scholar
  9. 9.
    McEvoy J, Stiller RL, Farr R: Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 1986;6:133–138.PubMedCrossRefGoogle Scholar
  10. 10.
    Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79–91.PubMedGoogle Scholar
  11. 11.
    Baldessarini R, Katz B, Cotton P: Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984;141:748–752.PubMedGoogle Scholar
  12. 12.
    Smith RC, Baumgartner R, Shvartsburd A, et al: Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Psychopharmacology 1985;85:449–455.PubMedCrossRefGoogle Scholar
  13. 13.
    Mavroidis ML, Kanter DR, Hirschowitz J, et al: Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 1983;81:354–356.PubMedCrossRefGoogle Scholar
  14. 14.
    Van Putten T, Marder SR, May PR, et al: Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 1985;21:69–72.PubMedGoogle Scholar
  15. 15.
    Marder SR, Van Putten T, Mintz J, et al: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025–1029.PubMedGoogle Scholar
  16. 16.
    Kane JM, Woerner M, Borenstein M, et al: Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254–258.PubMedGoogle Scholar
  17. 17.
    Gardos G, Perenyi A, Cole JO, et al: Tardive dyskinesia: changes after three years. J Clin Psychopharmacol 1983;3:315–318.PubMedGoogle Scholar
  18. 18.
    Casey DE: Tardive dyskinesia: what is the natural history? Int Drug Ther Newslett 1983;18:13–16.Google Scholar
  19. 19.
    Kane JM, Cooper TB, Sachar EJ, et al: Clozapine: plasma levels and prolactin response. Psychopharmacology 1981;73:184–187.PubMedCrossRefGoogle Scholar
  20. 20.
    Honigfeld G, Patin J, Singer J: Clozapine: antipsychotic activity in treatment- resistant schizophrenics. Adv Ther 1984;1:77–97.Google Scholar
  21. 21.
    Giffith RW, Saameli K: Clozapine and agranulocytosis. Lancet 1975;ii:657.CrossRefGoogle Scholar
  22. 22.
    Lieberman JA, Johns CA, Kane JM, et al: Clozapine-induced agranulocytosis: noncross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271–277.PubMedGoogle Scholar
  23. 23.
    Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789–796.PubMedGoogle Scholar
  24. 24.
    Lieberman JA, Kane J, Johns C: Clozapine: guidelines for clinical management. Submitted, J Clin Psychiatry.Google Scholar
  25. 25.
    Siris SG, Morgan V, Vagerstrom R, et al: Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 1987;44:533–539.PubMedGoogle Scholar
  26. 26.
    Siris SG, Adan F, Cohen M, et al: Targeted treatment of depression-like symptoms in schizophrenia. Psychopharmacol Bull 1987;23:85–89.PubMedGoogle Scholar
  27. 27.
    Brenner R, Shopsin B: The use of monoamine oxidase inhibitors in schizophrenia. Biol Psychiatry 1980;15:633–647.PubMedGoogle Scholar
  28. 28.
    Prusoff BA, Williams DH, Weissman MM, et al: Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry 1979;36:569–575.PubMedGoogle Scholar
  29. 29.
    Carpenter WT Jr: Thoughts on the treatment of schizophrenia. Schizophr Bull 1986;12:527–539.PubMedGoogle Scholar
  30. 30.
    Goldberg SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985;11:453–456.PubMedGoogle Scholar
  31. 31.
    Crow TJ: Molecular pathology of schizophrenia: more than one disease process? Br Med J 1980;280:66–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Kolivakis T, Azian H, Kingstone E: A double-blind comparison of pimozide and chlorpromazine in the maintenance of chronic schizophrenic patients. Curr Ther Res 1974;16:998–1004.PubMedGoogle Scholar
  33. 33.
    Haas S, Beckmann H: Pimozide versus haloperidol in acute schizophrenia: a double-blind controlled study. Pharmacopsychiatry 1982;15:70–74.CrossRefGoogle Scholar
  34. 34.
    Lapierre WD: A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry 1978;135:956–959.PubMedGoogle Scholar
  35. 35.
    Davis JM: Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975;132:1237–1245.PubMedGoogle Scholar
  36. 36.
    Kane JM, Lieberman JA: Maintenance pharmacotherapy in schizophrenia, in Meltzer HY (ed): Psychopharmacology, The Third Generation of Progress: The Emergence of Molecular Biology and Biological Psychiatry. New York, Raven Press, 1988.Google Scholar
  37. 37.
    Kane J (ed): Drug Maintenance Strategies in Schizophrenia. Washington, DC, American Psychiatry Press, 1984.Google Scholar
  38. 38.
    Kane JM, Rifkin A, Woerner M, et al: Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893–896.PubMedGoogle Scholar
  39. 39.
    Marder SR, Van Putten T, Mintz J, et al: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025–1029.PubMedGoogle Scholar
  40. 40.
    Marder SR, Van Putten T, Mintz J, et al: Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518–521.PubMedGoogle Scholar
  41. 41.
    Hogarty GE, McEvoy JP, Munetz M, et al: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: Results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797–805.PubMedGoogle Scholar
  42. 42.
    Herz MI, Melville C: Relapse in schizophrenia. Am J Psychiatry 1980;137:801–805.PubMedGoogle Scholar
  43. 43.
    Degkwitz R, Binsack HF, Herkert H, et al: Zum problem der persistierenten extrapyramidalen hyperkinesen nach langfristiger anwendung von neuroleptika. Nervenarzt 1967;38:170–174.PubMedGoogle Scholar
  44. 44.
    Lieberman JA, Kane JM (eds): Predictors of Relapse in Schizophrenia. Washington DC, American Psychiatric Press, 1986.Google Scholar
  45. 45.
    Lieberman JA, Kane JM, Sarantakos S, et al: Prediction of relapse in schizo¬phrenia. Arch Gen Psychiatry 1987;44:597–603.PubMedGoogle Scholar
  46. 46.
    Janowsky DS, El-Yousef K, Davis JM, et al: Provocations of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973;28:185–191.PubMedGoogle Scholar
  47. 47.
    Angrist B, Rotrosen J, Gershon SL: Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology 1980,67:31–38.PubMedCrossRefGoogle Scholar
  48. 48.
    Cheung HK: Schizophrenics fully remitted on neuroleptics for 3–5 years: to stop or continue drugs? Br J Psychiatry 1981;138:490–494.PubMedCrossRefGoogle Scholar
  49. 49.
    Hogarty GE, Ulrich RF, Mussare F, et al: Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Sys 1976;37:494–500.Google Scholar
  50. 50.
    Johnson DAW: The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 1976;53:298–301.PubMedCrossRefGoogle Scholar
  51. 51.
    Dencker SJ, Lepp M, Malm U: Do schizophrenics well-adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatr Scand 1980;279:64–76.Google Scholar
  52. 52.
    Johnson DAW: Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 1979;135:524–530.PubMedCrossRefGoogle Scholar
  53. 53.
    Wistedt B: A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981;64:65–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • John M. Kane

There are no affiliations available

Personalised recommendations